Utami Auliasari M, Rendrayani Farida, Khoiry Qisty A, Alfiani Fitri, Kusuma Arif S W, Suwantika Auliya A
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Faculty of Health Science, Universitas Muhammadiyah Cirebon, Cirebon, West Java, Indonesia.
J Multidiscip Healthc. 2022 Sep 13;15:2067-2076. doi: 10.2147/JMDH.S372000. eCollection 2022.
WHO reported that 5.5 million people died in the world because of COVID-19. One of the efforts to mitigate the pandemic is administrating the vaccines globally.
The objective of this study was to review cost-effectiveness analysis of COVID-19 vaccination in low- and middle-income countries (LMICs).
We searched PubMed and EBSCO for the eligible studies with inclusion criteria using cost-effectiveness analysis, free full text, low-middle-income countries, and the publication date since the last year. Four reviewers conducted the review independently.
The review identified four articles meeting the eligibility criteria. The settings were LMICs. Different perspectives and economic modelling used by the countries confirmed a similar result. They all explained that vaccination could prevent the infection spread and mortality caused by COVID-19 and showed high cost-effectiveness values.
Administering COVID-19 vaccines was cost-effective and even cost-saving. The studies found that vaccination was more cost-effective in reducing the spread of the COVID-19 virus and the mortality it caused than no vaccination.
世界卫生组织报告称，全球有550万人死于新冠肺炎。全球接种疫苗是缓解疫情的措施之一。
本研究的目的是回顾低收入和中等收入国家（LMICs）新冠肺炎疫苗接种的成本效益分析。
我们在PubMed和EBSCO中搜索符合纳入标准的研究，使用成本效益分析、免费全文、低收入和中等收入国家以及去年以来的出版日期。四位评审员独立进行评审。
该综述确定了四篇符合入选标准的文章。研究背景为低收入和中等收入国家。各国采用的不同视角和经济模型证实了类似的结果。他们都解释说，接种疫苗可以预防新冠肺炎的感染传播和死亡，并显示出高成本效益值。
接种新冠肺炎疫苗具有成本效益，甚至可以节省成本。研究发现，与不接种疫苗相比，接种疫苗在减少新冠肺炎病毒传播及其造成的死亡方面更具成本效益。
